Viral interleukin‐10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles
Open Access
- 8 May 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (5) , 1298-1308
- https://doi.org/10.1002/art.10227
Abstract
Objective To evaluate the potential of viral interleukin-10 (vIL-10) gene therapy as an approach to prevent wear debris–induced inflammation, osteoclastogenesis, and bone resorption as it relates to periprosthetic osteolysis in patients with total joint replacements. Methods Replication-defective adenovirus vectors expressing vIL-10 (AdvIL-10) or LacZ (AdLacZ) target genes were used to transduce fibroblast-like synoviocytes (FLS) in vitro, and the effects of these cells on wear debris–induced proinflammatory cytokine production and receptor activator of nuclear factor κB ligand + macrophage colony-stimulating factor splenocyte osteoclastogenesis were assessed by enzyme-linked immunosorbent assay and tartrate-resistant acid phosphatase assay. The effects of AdvIL-10 administration on wear debris–induced osteolysis in vivo were analyzed using the mouse calvaria model, in which AdLacZ was used as the control. Results In the presence of AdLacZ-infected FLS, titanium particle–stimulated macrophages exhibited a marked increase in secretion of tumor necrosis factor α (TNFα) (6.5-fold), IL-6 (13-fold), and IL-1 (5-fold). Coculture with AdvIL-10–transduced FLS suppressed cytokine secretion to basal levels, while addition of an anti–IL-10 neutralizing antibody completely blocked this effect. The vIL-10–transduced FLS also inhibited osteoclastogenesis 10-fold in an anti–IL-10–sensitive manner. In vivo, titanium implantation resulted in a 2-fold increase in osteoclasts (P < 0.05) and in a 2-fold increase in sagittal suture area (P < 0.05). This increase over control levels was completely blocked in mice receiving intraperitoneal injections of AdvIL-10, all of whom had measurable serum vIL-10 levels for the duration of the experiment. Immunohistochemistry demonstrated reduced cyclooxygenase 2 and TNFα expression in AdvIL-10–infected animals. Conclusion This study demonstrates that gene delivery of vIL-10 inhibits 3 processes critically involved in periprosthetic osteolysis: 1) wear debris–induced proinflammatory cytokine production, 2) osteoclastogenesis, and 3) osteolysis.Keywords
This publication has 58 references indexed in Scilit:
- Breakthrough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealedCurrent Orthopaedic Practice, 2000
- AnticytokinesOsteoarthritis and Cartilage, 1999
- Immunological defects in mice with a targeted disruption in Bcl-3.Genes & Development, 1997
- Viral IL-10 gene therapy inhibits TNF-α and IL-1β, not IL-6, in the newborn endotoxemic mouseJournal of Pediatric Surgery, 1996
- Interleukin‐10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast‐like cells in rat bone marrow culture systemJournal of Cellular Physiology, 1995
- Immunosuppressive and Anti-inflammatory Properties of Interleukin 10Annals of Medicine, 1995
- Macrophage deactivation by interleukin 10.The Journal of Experimental Medicine, 1991
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.The Journal of Experimental Medicine, 1991
- Expression of Interleukin-10 Activity by Epstein-Barr Virus Protein BCRF1Science, 1990
- Heterogeneity of Hematopoietic Cells Immortalized by v-myc/v-raf Recombinant Retrovirus Infection of Bone Marrow or Fetal LiverJNCI Journal of the National Cancer Institute, 1989